GPR39 and type 2 diabetes mellitus: To clarify the role of endogenous GPR39 and identify the potential for pharmacological modification of GPR39 activity to modify glucose-stimulated insulin secretion and be a potential treatment for T2D, we have identified potent and selective GPR39 agonists and tested their acute insulinotropic effects in normal mice and in rodent models of T2D.